OR WAIT 15 SECS
Vifor Pharma and Angion Biomedica have signed a license agreement that will see the commercialization of late-stage product, ANG-3777.
Vifor Pharma and Angion Biomedica have signed a license agreement that will see the commercialization of late-stage product, ANG-3777, it was announced in a Nov. 9, 2020 press release.
ANG-3777 is a first-in-class small-molecule hepatocyte growth factor (HGF) mimetic, which is currently being developed for the treatment of delayed graft function (DGF) and cardiac-surgery-associated acute kidney injury (CSA-AKI). Under the terms of the agreement, Vifor Pharma will receive an exclusive global license, excluding China, Taiwan, Hong Kong, and Macau, for all ANG-3777 nephrology indications. Angion will receive up to US $80 million, including a US $30 million upfront payment, US $30 million equity investment, and US $20 million clinical study milestone payments.
“This agreement highlights the leadership position that Vifor Pharma has developed in the nephrology space and the fact that it has become the company of choice for organizations committed to partnering innovative nephrology focused assets,” said Stefan Schulze, CEO of Vifor Pharma, in the press release. “Angion is an excellent partner with an outstanding expertise leading to the development of this exciting asset and other pipeline products. We look forward to working closely with Angion, who will be responsible for the ongoing development program of ANG-3777, and to leveraging our commercial expertise to bring this highly promising, innovative treatment with a unique mode of action to patients suffering from DGF and CSA-AKI. These are both critical conditions, currently without any effective or approved therapies.”
“Vifor Pharma is one of the world leaders in the nephrology space and we are very excited to partner with them on the commercialization of ANG 3777 for nephrology indications,” added Dr. Jay Venkatesan, president and CEO of Angion, in the press release. “This is a major milestone for the team at Angion who has worked for many years to develop ANG-3777 as a therapy for patients with acute kidney injuries. We look forward to Phase 3 data in DGF towards the end of 2021 and working with Vifor Pharma to potentially bring ANG-3777 to nephrology patients worldwide.”
Source: Vifor Pharma